Myelodysplastic Syndromes (MDS)

What is Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes (MDS), also known as myelodysplasia, are a group of blood cancers or disorders in which the bone marrow does not produce enough healthy, mature blood cells. Instead, it makes abnormal or immature cells (often called blasts) that don’t function properly and may die early.

This leads to cytopenias — low counts of one or more blood cell types: red blood cells (anemia), white blood cells (increasing infection risk), and/or platelets (causing bleeding/bruising).

MDS is considered a type of myeloid neoplasm and can sometimes progress to acute myeloid leukemia (AML) — roughly 1 in 3 cases may transform over time.

What Happens in MDS?

Bone marrow stem cells acquire genetic changes (mutations) that disrupt normal blood cell development (ineffective hematopoiesis).
The marrow is often hypercellular (crowded) but produces dysfunctional cells.
Dysplasia (abnormal cell appearance) is a hallmark seen under the microscope.

It primarily affects older adults (most common over age 60–65), though it can occur at any age, including rarely in children.

Types of MDS

Classification is based on blood/bone marrow findings, genetic abnormalities, and blast percentage (updated WHO and ICC systems). Common categories include:

MDS with low blasts (and specific genetic features like SF3B1 mutation or del(5q)).
MDS with multilineage dysplasia.
MDS with excess blasts.
MDS/AML (higher blast counts approaching leukemia).

Common Symptoms

Many people have no symptoms early on (found incidentally on blood tests). When present:

Fatigue, weakness, shortness of breath (from anemia).
Frequent or severe infections (low white cells).
Easy bruising, bleeding, petechiae, or prolonged bleeding (low platelets).
Pale skin, dizziness, headaches.
In advanced cases: bone pain or weight loss.

Causes and Risk Factors

Acquired genetic mutations in bone marrow cells (not usually inherited).
Prior chemotherapy or radiation (therapy-related MDS).
Exposure to chemicals (e.g., benzene, pesticides), smoking, or heavy metals.
Older age is the biggest risk factor.
Some cases link to prior blood disorders or genetic predispositions.

Diagnosis

Complete blood count (CBC) showing cytopenias.
Peripheral blood smear.
Bone marrow aspiration and biopsy (key test — shows dysplasia, blast percentage, and cellularity).
Cytogenetic analysis and next-generation sequencing for mutations (e.g., TP53, SF3B1).
Rule out other causes of low blood counts.

Treatment and Management

No single cure for most patients, but treatments aim to improve blood counts, reduce symptoms, prevent complications, and improve quality of life:

Supportive care: Blood transfusions, platelet transfusions, antibiotics, growth factors (e.g., erythropoietin for anemia).
Drug therapy: Hypomethylating agents (azacitidine, decitabine), lenalidomide (especially for del(5q)), chemotherapy, targeted therapies, or luspatercept for certain anemia cases.
Allogeneic stem cell transplant — the only potential curative option, mainly for younger/fit patients or higher-risk MDS.
Clinical trials for new agents.

Prognosis

Varies widely. Doctors use scoring systems like IPSS-M (Molecular International Prognostic Scoring System) that consider blood counts, blast percentage, cytogenetics, and mutations to estimate risk (very low to very high). Lower-risk MDS may allow many years of good quality life with supportive care; higher-risk has shorter survival and higher leukemia risk.

Note: MDS is distinct from Myelofibrosis (MF) — MF involves bone marrow scarring/fibrosis and often enlarged spleen, while MDS is primarily about ineffective blood cell production with dysplasia. They are separate but both fall under myeloid neoplasms and can occasionally overlap.

This is general educational information. MDS is highly individualized — consult a hematologist/oncologist specializing in MDS/MPNs for diagnosis or treatment. Excellent resources include: